Adelphi Values to lead Oncology Forum

On October 5th 2015, Alan Shields, PhD from Adelphi Values USA will be chairing a session entitled ‘Use and Usefulness of PRO Endpoints in Oncology Trials’ to be held from 12pm to 5pm.  This session is part of a broader DIA (Drug Information Association) conference in Bethesda, Maryland, USA entitled ‘Advancing the Science of Study Endpoints’.  The purpose of the conference is to bring together key stakeholders and professionals from the pharmaceutical industry, regulatory agencies and expert workgroups to generate practical solutions to the challenges associated with study endpoints and will focus on the key product development areas of oncology, pediatrics and rare diseases.

As chair of the oncology session, Alan will lead a discussion with examples, insights and practical knowledge regarding the use of PRO-based endpoints as primary efficacy endpoints in oncology trials and their value in the kind of open label trials that are routinely conducted for cancer treatments.  Attendees will learn about study endpoint challenges and the focus of the meeting will be on generating solutions that can be applied in clinical development programs.

As Vice President of the Endpoint Development & Outcomes Assessment practice at Adelphi Values USA, Alan provides scientific, regulatory and strategic PRO measurement services within the pharmaceutical industry and continues to publish in both industry and academic journals. When asked about his involvement in the conference Alan said “It is an honor to be invited to lead the oncology track.  I have worked in the industry for many years and PRO endpoints in oncology are an important part of the patient journey, and to be able to share my knowledge at the DIA conference is an exciting prospect”.

The DIA is the premier professional community for the health care product development ecosystem and provides a neutral and transparent forum for the exchange of ideas and collaboration.  Should you wish to register to attend this presentation please contact the DIA for further details.

If you would like further information on this conference presentation or on any of our broader patient-centred research solutions, please contact us via our website or alternatively email us at